EMICIZUMAB DATA
Quality of Life
The Genentech resources below are patient-friendly summaries of data related to emicizumab and quality of life topics. These patient-friendly summaries include studies with the strongest and most relevant data and are provided only for educational purposes. You are encouraged to discuss any questions you have about your condition and any current or potential treatments with your healthcare provider.
Quality of Life Results With HEMLIBRA in Hemophilia A Without Inhibitors
Quality of Life Results With HEMLIBRA in Hemophilia A With Inhibitors
Select publications and scientific data presentations with the strongest and most relevant data are provided below.
The Effect of Emicizumab Prophylaxis on Health-Related Outcomes in Persons With Haemophilia A With Inhibitors: HAVEN 1 Study.
Oldenburg J, Mahlangu JN, Bujan W, et al. Haemophilia. 2019;25:33–44.
Emicizumab Prophylaxis in Paediatric Persons With Haemophilia A (PwHA) With Inhibitors: Impact on Health-Related Outcomes and Caregiver Burden in the HAVEN 2 Study
Mancuso ME, Mahlangu J, Sidonio RF, et al. Presented at EAHAD; February 7–9, 2018.
Health-Related Quality of Life and Caregiver Burden of Emicizumab in Children With Haemophilia A and Factor VIII Inhibitors - Results From the HAVEN 2 Study
Mancuso ME, Mahlangu J, Sidionio R, et al. Haemophilia. 2020;26(6):1009-1018.
Emicizumab Prophylaxis Improves Long-Term Physical Health Scores in Persons With Haemophilia A (PwHA) With or Without Inhibitors: Update From the HAVEN 3 and HAVEN 4 Studies
Skinner M, Negrier C, Paz-Priel I, et al. Presented at ISTH; July 6–10, 2019.